^
    FGFR1 rearrangement + Chr t(8;13)
    T Acute Lymphoblastic Leukemia
    Tyrosine kinase inhibitor
    Resistant: C4 – Case Studies
    Blood - 2 weeks
    CD38 expression
    T Acute Lymphoblastic Leukemia
    isatuximab-irfc
    Sensitive: D – Preclinical
    Mol Cancer Ther - 3 weeks
    No biomarker
    T Acute Lymphoblastic Leukemia
    nelarabine
    Sensitive: A1 - Approval
    No biomarker
    T Acute Lymphoblastic Leukemia
    cyclophosphamide oral + etoposide oral + nelarabine
    Sensitive: A2 - Guideline
    No biomarker
    T Acute Lymphoblastic Leukemia
    prednisone + vincristine + daunorubicin + nelarabine + pegaspargase
    Sensitive: A2 - Guideline
    TP53 mutation
    T Acute Lymphoblastic Leukemia
    venetoclax
    Sensitive: C1 - Off-label
    NOTCH1 mutation
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    FBXW7 mutation
    T Acute Lymphoblastic Leukemia
    prednisone
    Resistant: C3 – Early Trials
    HGF-L
    T Acute Lymphoblastic Leukemia
    mogamulizumab
    Resistant: C3 – Early Trials
    NOTCH1 L1574Q
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    NOTCH1 V1577E
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    NOTCH1 L1600Q
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    NOTCH1 L1585R
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    NOTCH1 V1577A
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    NOTCH1 L1600P
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    NOTCH1 L1574P
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    NOTCH1 F1592S
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    NOTCH1 F1592C
    T Acute Lymphoblastic Leukemia
    prednisone
    Sensitive: C3 – Early Trials
    JAK3 mutation
    T Acute Lymphoblastic Leukemia
    tofacitinib
    Resistant: C4 – Case Studies
    SET-NUP214 fusion
    T Acute Lymphoblastic Leukemia
    ADE
    Sensitive: C4 – Case Studies
    MEF2C overexpression
    T Acute Lymphoblastic Leukemia
    ABT-737
    Sensitive: D – Preclinical
    PAK2 overexpression
    T Acute Lymphoblastic Leukemia
    FRAX597 + PF-3758309
    Sensitive: D – Preclinical
    MCL1 underexpression
    T Acute Lymphoblastic Leukemia
    venetoclax + BI 6727
    Sensitive: D – Preclinical
    MYC underexpression
    T Acute Lymphoblastic Leukemia
    venetoclax + BI 6727
    Sensitive: D – Preclinical
    CCND3 deletion
    T Acute Lymphoblastic Leukemia
    palbociclib
    Sensitive: D – Preclinical
    JAK3 M511I
    T Acute Lymphoblastic Leukemia
    tofacitinib XR
    Sensitive: D – Preclinical
    JAK3 M511I
    T Acute Lymphoblastic Leukemia
    ruxolitinib
    Sensitive: D – Preclinical
    NOTCH1 mutation
    T Acute Lymphoblastic Leukemia
    CB-839
    Sensitive: D – Preclinical
    NOTCH1 mutation
    T Acute Lymphoblastic Leukemia
    IACS-010759
    Sensitive: D – Preclinical
    BCL2L1 underexpression
    T Acute Lymphoblastic Leukemia
    venetoclax + BI 6727
    Sensitive: D – Preclinical
    PRC2 mutation
    T Acute Lymphoblastic Leukemia
    JQ-1
    Sensitive: D – Preclinical
    PCDHB15 overexpression
    T Acute Lymphoblastic Leukemia
    ruxolitinib
    Sensitive: D – Preclinical
    NUP214-ABL1 rearrangement
    T Acute Lymphoblastic Leukemia
    dasatinib
    Sensitive: D – Preclinical
    TCRB-LCK translocation
    T Acute Lymphoblastic Leukemia
    dasatinib
    Sensitive: D – Preclinical
    RPL10 R98S
    T Acute Lymphoblastic Leukemia
    venetoclax
    Sensitive: D – Preclinical
    NT5C2 R367Q
    T Acute Lymphoblastic Leukemia
    mercaptopurine
    Resistant: D – Preclinical